YU70201A - Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja - Google Patents

Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja

Info

Publication number
YU70201A
YU70201A YU70201A YUP70201A YU70201A YU 70201 A YU70201 A YU 70201A YU 70201 A YU70201 A YU 70201A YU P70201 A YUP70201 A YU P70201A YU 70201 A YU70201 A YU 70201A
Authority
YU
Yugoslavia
Prior art keywords
carnitine
esters
active compounds
pharmacologically active
carnatines
Prior art date
Application number
YU70201A
Other languages
English (en)
Inventor
Claudio Pisano
Maria Ornella Tinti
Mose Santaniello
Luciano Critelli
Giovanni Salvatori
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority to MEP-240/08A priority Critical patent/MEP24008A/xx
Publication of YU70201A publication Critical patent/YU70201A/sh
Publication of RS50911B publication Critical patent/RS50911B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Opisani su estri L-karnitina i alkanoil L-kamitina koji se mogu koristiti kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja. Takodje, opisani su novi estri L-karnitina i alkanoil L-karnitina formule (I) gde su grupe R definisane u opisu.
YUP-702/01A 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja RS50911B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-240/08A MEP24008A (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti

Publications (2)

Publication Number Publication Date
YU70201A true YU70201A (sh) 2004-07-15
RS50911B RS50911B (sr) 2010-08-31

Family

ID=11406659

Country Status (34)

Country Link
US (4) US6797281B1 (sh)
EP (3) EP1426044B1 (sh)
JP (2) JP4703855B2 (sh)
KR (2) KR100684378B1 (sh)
CN (2) CN100402017C (sh)
AT (2) ATE317257T1 (sh)
AU (2) AU776301B2 (sh)
BG (3) BG65501B1 (sh)
BR (2) BRPI0017460B1 (sh)
CA (2) CA2370143C (sh)
CZ (1) CZ302628B6 (sh)
DE (2) DE60017388T2 (sh)
DK (2) DK1183228T3 (sh)
EA (2) EA006021B1 (sh)
EE (2) EE05514B1 (sh)
ES (2) ES2234591T3 (sh)
HK (1) HK1045145B (sh)
HR (1) HRP20010740B1 (sh)
HU (1) HU229366B1 (sh)
IL (4) IL145765A0 (sh)
IS (2) IS2476B (sh)
IT (1) IT1306129B1 (sh)
ME (2) ME00113B (sh)
MX (1) MXPA01010359A (sh)
NO (2) NO327742B1 (sh)
NZ (2) NZ515270A (sh)
PL (2) PL211710B1 (sh)
PT (2) PT1426044E (sh)
RS (3) RS52682B (sh)
SI (2) SI1426044T1 (sh)
SK (2) SK287253B6 (sh)
TR (2) TR200102941T2 (sh)
WO (1) WO2000061543A2 (sh)
ZA (1) ZA200109291B (sh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE10113446A1 (de) † 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
EP2108362B1 (en) 2002-06-26 2013-05-29 MediGene AG A cationic liposomal preparation comprising a taxane
PT2286795T (pt) * 2002-06-26 2017-01-27 Syncore Biotechnology Co Ltd Processo de produção de uma preparação lipossomal catiónica que compreende um composto lipófilo
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
US20080095834A1 (en) * 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CN101232872A (zh) * 2005-08-10 2008-07-30 诺瓦提斯公司 7-(叔丁氧基)亚氨基甲基喜树碱的制剂
MX2008001965A (es) * 2005-08-10 2008-03-26 Novartis Ag Composiciones en microparticulas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecina.
US20100178325A1 (en) * 2006-08-23 2010-07-15 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
WO2008094959A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
WO2008101173A2 (en) * 2007-02-16 2008-08-21 Cornell University Biodegradable compositions and materials
WO2008144881A1 (en) 2007-05-28 2008-12-04 Genesis Group Inc. Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
EP2265645A4 (en) * 2008-03-13 2011-03-23 Perkinelmer Health Sci Inc ENZYMATIC SUBSTRATES FOR MULTIPLE DETECTION SYSTEMS
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2014145418A1 (en) 2013-03-15 2014-09-18 Perkinelmer Health Sciences, Inc. Compounds and methods relating to testing for lysosomal storage disorders
MX2018010586A (es) 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.
US11591287B2 (en) 2017-06-06 2023-02-28 Wayne State University Antifouling zwitterionic polymer coating and reverse coating method
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
CA2085354C (en) * 1990-06-15 2002-08-27 Claude Piantadosi Ether lipid-nucleoside covalent conjugates
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
JP2001516329A (ja) * 1995-06-07 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリヌクレオチド複合体の安定化
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
EP0960204A4 (en) * 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
EA006021B1 (ru) 2005-08-25
HK1092732A1 (en) 2007-02-16
AU2004224958B2 (en) 2007-11-22
EP1435232A1 (en) 2004-07-07
CA2370143A1 (en) 2000-10-19
HK1045145A1 (en) 2002-11-15
US7585519B2 (en) 2009-09-08
DE60025961T2 (de) 2006-08-17
WO2000061543A3 (en) 2001-01-11
KR20010113794A (ko) 2001-12-28
IS2539B (is) 2009-09-15
NZ528874A (en) 2005-09-30
BG65501B1 (bg) 2008-10-31
EE201100028A (et) 2011-08-15
PL211710B1 (pl) 2012-06-29
EP1183228A2 (en) 2002-03-06
CA2650202A1 (en) 2000-10-19
KR20060113799A (ko) 2006-11-02
CA2370143C (en) 2011-06-21
PT1183228E (pt) 2005-04-29
AU2004224958A1 (en) 2004-11-25
PT1426044E (pt) 2006-06-30
ATE317257T1 (de) 2006-02-15
HUP0201446A3 (en) 2002-11-28
TR200202358T2 (tr) 2002-12-23
AU776301B2 (en) 2004-09-02
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
JP4703855B2 (ja) 2011-06-15
HU229366B1 (en) 2013-11-28
IT1306129B1 (it) 2001-05-30
JP2011042657A (ja) 2011-03-03
BR0009765B1 (pt) 2013-11-05
US20050079209A1 (en) 2005-04-14
DK1183228T3 (da) 2005-05-17
IS6095A (is) 2001-09-28
US6797281B1 (en) 2004-09-28
NO336949B1 (no) 2015-11-30
SK14312001A3 (sk) 2002-02-05
DE60017388T2 (de) 2006-03-30
ZA200109291B (en) 2002-08-16
EE200100518A (et) 2002-12-16
EA004459B1 (ru) 2004-04-29
HRP20010740B1 (en) 2005-08-31
AU4312300A (en) 2000-11-14
IL175366A (en) 2010-12-30
CN100402017C (zh) 2008-07-16
BG105971A (en) 2002-08-30
NO20014985L (no) 2001-10-12
SI1183228T1 (en) 2005-04-30
IL145765A (en) 2007-07-04
EP1183228B1 (en) 2005-01-12
SK288246B6 (sk) 2015-03-03
MEP24008A (en) 2010-06-10
DE60025961D1 (de) 2006-04-20
CN1359370A (zh) 2002-07-17
ATE286873T1 (de) 2005-01-15
BG109876A (en) 2008-02-29
JP2002541238A (ja) 2002-12-03
SI1426044T1 (sl) 2006-04-30
EE05514B1 (et) 2012-02-15
HUP0201446A2 (en) 2002-08-28
CN1263730C (zh) 2006-07-12
ITRM990220A1 (it) 2000-10-13
EA200300745A1 (ru) 2003-12-25
NO327742B1 (no) 2009-09-14
DE60017388D1 (de) 2005-02-17
CZ20013617A3 (cs) 2002-02-13
EP1426044A1 (en) 2004-06-09
KR100798499B1 (ko) 2008-01-28
NO20014985D0 (no) 2001-10-12
RS52682B (en) 2013-08-30
WO2000061543A2 (en) 2000-10-19
BG65312B1 (bg) 2008-01-31
KR100684378B1 (ko) 2007-02-20
NO20085413L (no) 2001-10-12
IS8719A (is) 2008-03-07
ES2258688T3 (es) 2006-09-01
CA2650202C (en) 2012-12-11
TR200102941T2 (tr) 2002-05-21
EE05719B1 (et) 2014-08-15
DK1426044T3 (da) 2006-06-12
ES2234591T3 (es) 2005-07-01
RS20090448A (en) 2010-06-30
IL145765A0 (en) 2002-07-25
EA200101076A1 (ru) 2002-04-25
US7629003B2 (en) 2009-12-08
BR0009765A (pt) 2002-01-02
IL175366A0 (en) 2006-09-05
CN1823731A (zh) 2006-08-30
IS2476B (is) 2008-12-15
IL185486A0 (en) 2008-01-06
SK287253B6 (sk) 2010-04-07
HK1045145B (en) 2006-01-27
BRPI0017460B1 (pt) 2016-04-19
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
HRP20010740A2 (en) 2002-10-31
PL204418B1 (pl) 2010-01-29
US20070190128A1 (en) 2007-08-16
RS50911B (sr) 2010-08-31
ME00113B (me) 2010-10-10
CZ302628B6 (cs) 2011-08-10
JP5420507B2 (ja) 2014-02-19
EP1426044B1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
YU70201A (sh) Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobadjanje farmakološki aktivnih jedinjenja
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
DK1157037T3 (da) GCSF-konjugater
AU2274201A (en) Compounds and compositions for delivering active agents
RS50035B (sr) Farmaceutska kompozicija koja sadrži fenofibrat i postupak za njeno dobijanje
SE9904505D0 (sv) Novel compounds
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
MA26905A1 (fr) Derives de phenylglycine.
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
SE0003476D0 (sv) Compounds
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
MY139010A (en) 6-azo-5, 5'-dihydroxy -7,7'-disulfo-2-2'-dinaphthylamine derivatives
PT1244614E (pt) Inibidores de triptase
AU6832498A (en) Substituted benzyl oximino compounds
ATE241640T1 (de) Fusidinsäure-derivate
DK1173065T3 (da) Anvendelse af cellulosemikrofibriller i fermenterede mælkepræparater
IT1299172B1 (it) Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti
WO2003007922A3 (de) Arzneimittelformulierung enthaltend einen ltb4 antagonisten
CA2390631A1 (en) Carboxamide-substituted benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions